FBRX

$26.44

Market ClosedAs of Mar 17, 8:00 PM UTC

Forte Biosciences, Inc.

Historical Price

Price (Line)
Synthesizing Whystock Narrative...
Loading Financials...

Peer Comparison

JNJUNHPFE

Whystock Valuation Model

Calculated using a trailing P/E relative model adjusted by sector ROE and historical growth.
Current Price$26.44
Potential Upside
5%
Whystock Fair Value$27.76
Price
UndervaluedFair ValueOvervalued

Fundamentals

SectorHealthcare
IndustryBiotechnology

Forte Biosciences, Inc. operates as a clinical-stage biopharmaceutical company in the United States. The company's lead product candidate is the FB-102, a proprietary anti-CD122 monoclonal antibody therapeutic candidate for various autoimmune and aut...

Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$331.21M
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
High-beta play. Expect amplified moves vs. the broad market.
3.21
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROIC
Average efficiency. Growth may require heavy reinvestment.
-110.72%
Quick Ratio
Pristine liquidity. Sufficient cash to cover all near-term obligations.
7.23

Recent News

Zacks
Feb 25, 2026

Forte Biosciences (FBRX) Upgraded to Buy: Here's What You Should Know

Forte Biosciences (FBRX) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

BULLISH
Positive press. Headlines skewed toward growth and analyst upgrades.
Simply Wall St.
Feb 18, 2026

We Think Forte Biosciences (NASDAQ:FBRX) Can Afford To Drive Business Growth

There's no doubt that money can be made by owning shares of unprofitable businesses. For example, Forte Biosciences...

NEUTRAL
Neutral flow. Standard news cycle with no clear sentiment tilt.
Simply Wall St.
Jan 4, 2026

Chief Financial Officer of Forte Biosciences Picks Up 30% More Stock

Investors who take an interest in Forte Biosciences, Inc. ( NASDAQ:FBRX ) should definitely note that the Chief...

BULLISH
Positive press. Headlines skewed toward growth and analyst upgrades.
Simply Wall St.
Dec 12, 2025

Positive week for Forte Biosciences, Inc. (NASDAQ:FBRX) institutional investors who lost 1.7% over the past year

Key Insights Significantly high institutional ownership implies Forte Biosciences' stock price is sensitive to their...

BULLISH
Positive press. Headlines skewed toward growth and analyst upgrades.
Simply Wall St.
Sep 11, 2025

We're Hopeful That Forte Biosciences (NASDAQ:FBRX) Will Use Its Cash Wisely

Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...

BULLISH
Positive press. Headlines skewed toward growth and analyst upgrades.